The medicines market in Norway - prices and regulations
|
|
- Lillian Marsh
- 7 years ago
- Views:
Transcription
1 Design and print by Grafia Kommunikasjon AS / / Photo by Jens Sølvberg The medicines market in Norway - prices and regulations Apotekforeningen (The Norwegian Pharmacy Association) is the trade organisation for pharmacies in Norway and their owners. According to its rules, the organisation shall primarily work to secure the best possible and predictable framework terms for the pharmacies. Apotekforeningen fulfills some joint functions and service tasks on behalf of the trade. In addition the organisation shall work to secure the pharmacies a clear and valuable position within the health care system, the pharmacy profession and towards consumers. Apotekforeningen Postboks 5070 Majorstuen, 0301 Oslo telefon: , fax e-post: apotekforeningen@apotek.no August 2008
2 4 Prices and regulations i n d e x 1 INTRODUCTION 4 2 THE MARKET ONE MARKET - SEVERAL SUB-MARKETS 5 Reimbursed medicines 5 Non-reimbursed medicines 5 The hospital market and other professional customers 5 The market for non-prescription medicines 5 3 NORWEGIAN SYSTEMS FOR MEDICINES PRICE REGULATION MAXIMUM PRICES FOR PRESCRIPTION MEDICINES Review of maximum prices Trinnpris for generics - interchangeable, equivalent medicines NO PRICE REGULATION FOR SALES OF NON-PRESCRIPTION MEDICINES AND PRODUCTS 9 4 MEDICINES PRICE DEVELOPMENT IN NORWAY AND COST DEVELOPMENT FOR THE PUBLIC SECTOR 4.1 COST DEVELOPMENT IN THE MARKET FOR PRESCRIPTION MEDICINES PRICE DEVELOPMENT FOR SOME MEDICINES BEST SELLERS MEDICINES PRICES IN NORWAY COMPARED TO OTHER COUNTRIES PRICE SURVEY BY THE NORWEGIAN INSTITUTE FOR RESEARCH ECONOMICS AND 15 BUSINESS ADMINISTRATION (SNF) Background and method Results CONCLUSION 21
3 6 Prices and regulations Prices and regulations 5 1 i n t r o d u c t i o n This brochure provides a brief description of how medicine prices are regulated and the development of turnover and prices on medicines in Norway. The brochure also reproduces the results from a recent price comparison between Norway and the countries Norwegian authorities look to when maximum prices are set in Norway. The Norwegian Pharmacy Association has experienced steadily growing interest from other countries about Norway and the development in Norwegian medicines prices and the regulations of pharmacies and pharmaceuticals. This brochure describes in brief the price system, prices and medicines costs in Norway. The Norwegian Pharmacy Association hopes that this publication will be useful to readers who wish to learn more about the price level of medicines in Norway and the price regulation regimes and other circumstances that have contributed to this price level. 2 t h e m a r k e t 2.1 One market several sub-markets The Norwegian medicines market can be regarded as at least four different sub-markets: Reimbursed medicines, non-reimbursed medicines, the hospital market and the market for non-prescription medicines. The market mechanisms in these four sub-markets differ from one another. This is reflected in the regulations to which the sub-markets are subjected. Reimbursed medicines This is the largest of the sub-markets, with a turnover in 2007 of almost NOK 9.0 billion, out of a total turnover for prescription medicines of NOK 14.2 billion. This market only includes medicines used by individual patients outside institutions, and covers mainly medicines that are used over a long period for the treatment or prevention of chronic diseases. Medicines used in hospitals and other health care institutions are not part of this market, and are covered by another financing arrangement. The reimbursement system in Norway can in rough terms be divided in two: Reimbursements approved in advance (main rule) and individual reimbursements (exception rule). In addition, there are some minor systems that are not dealt with here. Reimbursements approved in advance A number of medicines and products are approved in advance for reimbursement for closely defined areas of use and terms and conditions. These medicines with reimbursable areas of use and reimbursement terms and conditions are listed and described on the so-called reimbursement list. The reimbursement list contains information about all reimbursable medicines and the terms and conditions on which these are reimbursable. The right to a reimbursement arises immediately when a doctor prescribes a reimbursement prescription. The total cost of reimbursement medicines according to this arrangement in 2007 was NOK 7.5 billion. Individual reimbursement A medicine that is not listed on the reimbursement list, or is to be used for another illness than that described in the reimbursement list, can only be reimbursed once an application has been made to the Norwegian Labour and Welfare Administration (NAV). If the Labour and Welfare Administration (NAV) grants the application, the patient may get the medicine on a reimbursement prescription. The total cost of reimbursements according to this arrangement in 2007 was NOK 1.2 billion. Reimbursed medicines In this sub-market are mainly paid for by the state. The patient normally pays only a co-payment of 36 percent, or a maximum of NOK 510 each time he receives medicines from the pharmacy. There is a ceiling for how much a patient should pay for contributions towards medicines, doctor s consultations and psychotherapy during the course of a year. In 2008, this ceiling was set at NOK 1740 in total. Since the patients themselves do not decide on which medicines to be used, and since national insurance pays for the greater part of the cost of the medicines, the price of a pharmaceutical does not affect a patient s purchase or use of the pharmaceutical to any great degree. None of the actors in the medicines supply chain can expect increased sales to any particular extent by reducing their prices to patients. Therefore, the foundations for price competition are weak. Non-reimbursed medicines In the market for non-reimbursed medicines, the patients themselves have to pay for all medicines used. It is therefore assumed that patients are more price conscious on this market than on the market for reimbursed medicines, even if it is still doctors who decide which medicines are to be used. Turnover on this sub-market in 2007 was NOK 2.6 billion. The hospital market and other professional customers The hospital market differs from the two markets already described, as there is a greater correlation between price and usage of a pharmaceutical. Hospitals themselves finance the medicines used for treating patients. Therefore, when choosing which medicines to use, they consider the price of the medicines to a greater degree, which stimulates price competition. Turnover on this sub-market in 2007 was NOK 2.8 billion. The market for non-prescription medicines The market for non-prescription medicines is the sub-market that most resembles other markets. In this market, users themselves decide which pharmaceutical to buy, and they pay the bill themselves. As in the hospital market, there is a correlation between price and choice of pharmaceutical, which simulates price competition. In 2007, pharmacies share of the turnover in this sub-market was NOK 2.0 billion. In addition, there is turnover from other points of sale than pharmacies, as grocery shops and others are allowed to sell a number of non-prescription medicines.
4 6 Prices and regulations Prices and regulations 7 3 n o r w e g i a n s y s t e m s f o r m e d i c i n e s p r i c e r e g u l a t i o n 3.1 Maximum prices for prescription medicines The authorities decide the maximum price for prescription medicines in Norway. Maximum prices are set using three steps: Step 1: Gather comparison prices from other countries The Norwegian Medicines Agency sets a maximum purchase price for pharmacies which is the average of the three lowest market prices (pharmacy purchasing price) for the pharmaceutical in the following nine countries: Sweden, Finland, Denmark, Germany, United Kingdom, Netherlands, Austria, Belgium and Ireland. The reason for using these nine countries is that they are regarded as the most relevant with which to compare Norway. Since the Norwegian price is set as the average of the three lowest observed prices for each product, Norwegian prices will always be among the three lowest observed prices at product level. Different countries may be the cheapest for the different products, but Norwegian prices will always be the average of the three cheapest. For this reason, the average price for all medicines as a whole will in all probability be lower in Norway than the average price in the countries with which we compare ourselves. This is illustrated in Tables 1 and 2: Table 1 illustrates three different medicines. For each of the products, prices for the corresponding product is gathered from the nine countries named. The Norwegian price is the average of the three lowest prices. The table illustrates how different countries can be the cheapest for different products, and that the Norwegian price will lie in a position between the three cheapest countries for each of the products. If we calculate the average price per country for all three medicines, we get table 2. Table 2 shows that the Norwegian method for determining maximum price ensures that medicines in Norway on average are cheaper than in most countries with which we normally compare ourselves. Step 2: Determination of mark-up The authorities have decided that pharmacies maximum mark-up shall consist of a percentage addition to the pharmacies purchase price combined with a fixed additional amount per package. Table 3. Pharmacy mark-up Pharmacy purchase price Percent increase Supplement in NOK per package NOK ,00 % NOK 21,50 NOK > 200 5,00 % NOK 21,50 The pharmacy mark-up for a pharmaceutical where the pharmacy s purchase price is NOK 300 would then be: Mark-up = (NOK 200 x 0.08) + (NOK 100 x 0.05) + NOK = NOK From the pharmacy s mark-up, the pharmaceutical turnover fee of 1.3 percent of pharmacy s purchase price is deducted. On this occasion, this would equal (NOK 300 x 0.013) = NOK 3.90 Table 2. Norwegian prices are lowest: Average* Country Price Norway 245 Austria 247 Belgium 250 Netherlands 254 Sweden 254 Denmark 258 Finland 258 Germany 259 Ireland 268 United Kingdom 278 *of the prices in Table 1 Table 1. Mathematical example calculation of maximum price in Norway Drug A Drug B Drug C Country Price Country Price Country Price Sweden 100 Belgium 200 Austria 400 Denmark 100 Netherlands 210 Belgium 430 Finland 115 Ireland 220 Germany 430 Germany 116 United Kingdom 220 Finland 430 Netherlands 116 Denmark 223 Netherlands 435 Austria 118 Austria 224 Sweden 436 Belgium 120 Sweden 227 Denmark 450 United Kingdom 124 Germany 230 Ireland 458 Ireland 125 Finland 230 United Kingdom 489 Norway 105 Norway 210 Norway 420 For narcotic drugs and addictive medicines, the pharmacy receives an extra NOK 10 in mark-up. Step 3: Value added tax The sum of the pharmacy s purchase price and the pharmacy s mark-up is subject to a value added tax of 25 percent. This amount is the maximum price the pharmacy can demand from a customer. The maximum retail price is therefore calculated as follows: Pharmacy purchase price NOK Pharmacy mark-up nok VAt nok = Maximum retail price NOK
5 8 Prices and regulations Prices and regulations Review of maximum prices The Norwegian Medicines Agency evaluates the prices of 300 of the most used prescription substances every year to ensure that the maximum prices reflect the price development in Europe. Reasons for changes in the maximum price may be, for instance, changes in the European price picture, changes in exchange rates or a pharmaceutical being withdrawn from one of the above-mentioned nine European countries. 3.3 Trinnpris for generics - interchangeable, equivalent medicines The Norwegian Medicines Agency determines which medicines are regarded as equivalent and thus interchangeable, and are therefore subject to generic substitution. Interchangeable medicines, or generic medicines, contain the same substances in the same doses and same formats (capsules, tablets, etc), but are manufactured by different producers. For 45 of the most used medicines on the Medicines Agency s interchange list, the authorities have decided that pharmacies shall offer patients at least one generic alternative at a price that is considerably lower than the maximum price. These prices are called trinnpris (stepped prices). For a medicine with an annual turnover higher than NOK 100 million and is included in the trinnpris -system, the price development will be as illustrated in Figure 4. Mathematical example: Pharmaceutical A is covered by a patent, has a maximum price of NOK 500 set by the authorities and a turnover of NOK 150 million. The patent expires and several manufacturers choose to launch generic alternatives to the previously patented pharmaceutical A. When at least one of these alternative suppliers can supply the Norwegian market, stable generic competition is said to have started. The Medicines Agency can then set a trinnpris which is 30 percent lower than the original maximum price. On this occasion, the trinnpris will be NOK No price regulation for sales of non-prescription medicines and products Pharmacies can decide themselves the prices for non-prescription medicines and non-pharmaceutical products. However, the government does impose maximum prices also for medical equipment and medical consumables. Six months after the introduction of a trinnpris, the price is cut further. As pharmaceutical A originally turned over NOK 150 million, a new trinnpris is set equivalent to a cut in the original maximum price of 75 percent. The new price is NOK 125. This is the price at which the pharmacies sell the pharmaceutical. Provided the consumption of the pharmaceutical remains unchanged, the annual turnover 12 months after the latest trinnpris was set would be 25 percent of the original turnover, or NOK 37.5 million. Table 4 shows that there is reason to set a new and lower stepped price, equivalent to a cut in the original maximum price of 80 percent. A new trinnpris price is set at NOK 100. This is done 18 months after stable generic competition started on the market. Table 4 Trinnpris Figur 4 The trinnpris system Time since stable generic competition started Sales below MNOK 100 (latest year of generic competition) Sales above MNOK 100 (latest year of generic competition) Annual sales above MNOK 100 after last price cut Pris Immediately -30 % -30 % After 6 months -55 % -75 % Further cut 12 months after latest cut -65 % (for pharmaceuticals with turnover higher than MNOK 15) -80 % (for pharmaceuticals with turnover higher than MNOK 30) -85 % (for pharmaceuticals with turnover higher than MNOK 100) Stabil generisk konkurranse 6 mnd 12 mnd etter siste kutt (18 mnd etter stabil generisk konkurranse)
6 10 Prices and regulations Legemiddelmarkedet 11 4 m e d i c i n e s p r i c e d e v e l o p m e n t i n n o r w a y a n d c o s t d e v e l o p m e n t f o r t h e p u b l i c s e c t o r 4.1 Cost development in the market for prescription medicines The growth in total pharmaceutical costs in Norway has stagnated over the last few years. The tendency is for a larger proportion of the total costs of prescription medicines to be paid by hospitals, and by patients themselves on non-reimbursed medicines. The amount falling within the national insurance area of responsibility (reimbursed medicines) is reducing, see Figure 7. Reimbursement costs for medicines measured in nominal NOK were lower in 2007 than in Figure 8 shows the results when all figures are indexed, so that the value in 2004 for all sub-markets for prescription medicines is 100. Table 5. Costs of prescription medicines divided into sub-markets nominal NOK (millions) Year Non-reimbursed medicines Reimbursed medicines Medicines used in hospitals Total value of prescription medicines Figure 7. Costs of prescription medicines divided up into sub-markets nominal NOK (millions) Figure 8. Relative distribution of medicines costs
7 12 Prices and regulations Prices and regulations 13 One of the causes of the strong growth in hospitals expenses for medicines in 2006 is that the responsibility for financing a group of very expensive medicines against serious rheumatic illnesses was transferred from the national insurance to the regional health enterprises (hospital owners). The tendency is for hospitals to use more expensive medicines. Figure 9 shows that the proportion of medicines turnover that falls within the reimbursement system constitutes a steadily falling proportion of prescription medicines. The total medicines turnover in Norway shows a reducing tendency at the same time as consumption in volume is increasing. This development means that prices have fallen over the period, and that consumption has changed in the direction of cheaper medicines. In graphic terms, the change in distribution between hospital use, non-refundable medicines and refundable medicines is illustrated in Figure 9. Table 6. Relative distribution of medicines costs , nominal, not price-adjusted (nominal NOKs) Figure 9. Relative distribution of medicines costs hospitals, refundable and non-refundable medicines Year Non-reimbursed medicines 100 % 109 % 113 % 121 % Reimbursed medicines 100 % 100 % 95 % 92 % Medicines used in hospitals 100 % 107 % 134 % 150 % Total value of prescription medicines 100 % 102 % 103 % 104 %
8 14 Prices and regulations Legemiddelmarkedet 15 5 m e d i c i n e s p r i c e s i n n o r w a y c o m p a r e d t o o t h e r c o u n t r i e s 4.2 Price development for some medicines best sellers The state maximum price regulation and the trinnpris -system have made sure that the price of medicines as a whole is falling. In Figure 10, the price development for seven of the most used/turned over prescription medicines is compared with the development of the general level of prices (consumer retail price index, CRPI) and the average blue-collar worker wage. The first four products are patented medicines, while the last three are interchangeable medicines subject to generic substitution and included in the trinnpris system. Figure 10 compares the levels in 2007 with levels in ,5% Figure 10 shows that both the average blue-collar worker wage and CRPI have risen, while the price of medicines has fallen during the period from 2003 up to and including Figure 10. Price development for some of the most sold pharmaceuticals vs. consumer retail price index and growth in wages. ( ) -31,8% -9,3% -25,6% -8,4% -16,9% 5.1 Price survey by the Norwegian Institute for Research in Economics and Business Administration (SNF) Background and method In May 2008, the Ministry of Health and Care Services published their price survey carried out by the Institute for Research in Economics and Business Administration (SNF). Prices in Norway were compared to prices in nine reference countries: Belgium, Denmark, Finland, Ireland, Netherlands, United Kingdom, Sweden, Germany and Austria. (See Chapter 3.1) The survey covers the 300 most turned over pharmaceutical substances in Norway, and the prices are from the first six months of 2007, excluding value added tax. Since the prices are from the first six months of 2007, they do not include the effects of the price cuts on trinnpris -medicines implemented on 1 January The report has used several different methods for comparing prices. All the methods clearly point to medicines being cheaper in Norway. Results The price investigation shows that Norway is among the very cheapest countries, whether you look at: all medicines together, the segment for patented medicines, or the segment for medicines with generic competition. Norway is clearly the cheapest when you look only at medicines in the trinnpris -system. The investigation also shows that Norway has among the lowest wholesaler and pharmacy margins. Table 8 shows in index format (Norway = 100) what the Norwegian medicines consumption would have cost if volume-weighted prices from the different countries had been used ,2% Table ,9% -87,1% Norway Sweden Denmark Finland UK Germany Netherlands Belgium Austria Ireland -100 Seretide Lipitor Nexium Patenterte legemidler Byttbare legemidler Cipralex Amlodipin Simvastatin Sumatriptan Konsumprisindeksen Des Jan 2008 Industriarbeiderlønn All drugs ,6 113,8 123,7 104,4 138,7 117,4 156,7 122,7 234,6 Patent ,0 123,9 124,2 101,7 124,2 100,0 154,2 119,7 196,7 Off patent ,3 95,6 122,8 109,0 166,8 147,3 161,3 128,2 300,5 Trinnpris ,0 109,1 127,4 136,4 174,4 215,9 210,1 194,4 518,1 Table 7. Price changes over the period for some of the most turned over pharmaceuticals Pharmaceutical Used against Then (31/ ) Now (1/3 2008) Reduction Change in % Nexium Gastric ulcer % Lipitor Cholesterol % Seretide Asthma % Cipralex Depression % Amlodipin Heart disease % Simvastatin Cholesterol % Sumatriptan Migraine % 1
9 16 Prices and regulations Prices and regulations 17 In graphic terms, the price level of prescription medicines, irrespective of patent status, can be presented as in Figure 11. If we look closer at patented medicines, the price difference can be expressed graphically as in Figure 12. Figure 11. Public price - all Rx drugs Figure 12 confirms that the manner in which maximum prices are set in Norway ensures that maximum prices in Norway will be the lowest among the countries to which Norway is compared, see Chapter 3. During the period from which the price survey gathered data, the trinnpris -system included 31 substances. For a more detailed description of the principles of the trinnpris - system, see Chapter 3.3. Table 8 shows that price difference between Norway and other countries is greatest for these substances. In graphic terms, this can be shown as in Figure 13: Norway Sweden Denmark Finland UK Germany Belgium Austria Ireland Nether-lands Figure 12. Patented drug index Figure 13. Trinnpris index for generic drugs Norway Sweden Denmark Finland UK Germany Belgium Austria Ireland Nether-lands Norway Sweden Denmark Finland UK Germany Belgium Austria Ireland Nether-lands
10 18 Prices and regulations Prices and regulations 19 The trinnpris in Norway were cut further in January As the data used in the price survey dates from 2007, the effect of this price cut is not shown in the survey in question. The survey also establishes that distribution margins in Norway are among the lowest in the comparison countries, see Table 9 and Figure 14. The distribution margin is the total margin for pharmacies and wholesalers, defined as: Distribution margin = Pharmacy selling price. Pharmacy selling price Wholesaler purchase price The survey shows that only Sweden and Denmark have lower percentage margins than Norway. It is important to point out that this does not compare pharmacy mark-ups, but the mark-up for the distribution stage. The survey does therefore not provide a basis for stating anything about the differences in either pharmacy mark-ups or wholesaler mark-ups, but only the sum of the two. It is also important to notice that the margins here are percentages. A certain percentage increase of a low amount results in a lower increase in NOK than the same percentage increase of a higher amount. Since prices in Norway are low, there has to be a higher percentage margin in Norway in order for the distribution stage to receive the same amount in NOK as in other countries. 6 c o n c l u s i o n Most countries use one form or another of price or reimbursement regulations for medicines. The systems vary a lot from country to country. This must be considered in conjunction with the framework conditions, which may also vary, and the fact that there might be good reasons for different countries choosing different price and reimbursement systems. It is therefore not the case that a country which copies another country s price/reimbursement systems necessarily achieves the same result. Table 9. Distribution margins Norway Sweden Denmark Finland UK Germany Netherlands Belgium Austria Ireland Total 24,1 21,2 23,5 33,5 29,4 32,8 29,3 24,9 29,5 49,1 Patent 16,8 12,8 18,5 29,9 12,1 21,1 17,2 17,5 25,9 46,5 Off patent 32,9 31,5 29,6 37,9 50,4 47,2 43,9 33,9 33,9 52,2 Figure 14. Distribution margins % NorwaySweden Denmark Finland UK Germany Holland Belgium Austria Ireland
Global Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)13 DAF/COMP/GF/WD(2014)13 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 15-Jan-2014 English
More informationThe Swedish Pharmaceutical Reimbursement System
The Swedish Pharmaceutical Reimbursement System January 2007 www.lfn.se The Swedish Pharmaceutical Reimbursement System - A brief overview Sweden made some major changes to its reimbursement system in
More informationGeneric substitution of prescription drugs
Generic substitution of prescription drugs Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (2)2003 Author(s): Ilmo Keskimäki and Lauri Vuorenkoski
More informationNational Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations
National Centre for Pharmacoeconomics Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations Version 1.10 Please Note: This document may be updated periodically, therefore please refer
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)32 DAF/COMP/GF/WD(2014)32 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 30-Jan-2014 English
More informationFACTS AND FIGURES. Apotekforeningen
2010 FACTS AND FIGURES Pharmacies and Pharmaceuticals in Norway 2010 Apotekforeningen INDEX Key figures 2009 4 Pharmacies in Norway 5 About the pharmacy trade 6 Numbers of pharmacies and development 6
More informationp h a r m a c i e s i n n o r w a y : a n d o w n e r s h i p, s t r i c t p r o f e s -
2 Facts and figures Facts and figures 3 i n d e x 003 Pharmacies in Norway: Deregulation of establishment and ownership, strict professional regulation of operations 004 007 009 011 016 018 About the pharmacy
More informationThe Community Innovation Survey 2010 (CIS 2010)
The Community Innovation Survey 2010 (CIS 2010) THE HARMONISED SURVEY QUESTIONNAIRE The Community Innovation Survey 2010 FINAL VERSION July 9, 2010 This survey collects information on your enterprise s
More informationTHE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA
THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationTHE ROLE OF PUBLIC SUPPORT IN THE COMMERCIALISATION OF INNOVATIONS
Flash Eurobarometer THE ROLE OF PUBLIC SUPPORT IN THE COMMERCIALISATION OF INNOVATIONS REPORT Fieldwork: January February 2014 Publication: May 2014 This survey has been requested by the European Commission,
More information// BRIEF STATISTICS 2014
// BRIEF STATISTICS 2014 // TAXATION IN FINLAND Finland s taxation is subject to decisions by the Finnish Parliament, the European Union and the municipalities of Finland. It is governed by tax legislation,
More informationCENTRE FOR TAX POLICY AND ADMINISTRATION
ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT TRANSFER PRICING METHODS JULY 2010 Disclaimer: The attached paper was prepared by the OECD Secretariat. It bears no legal status and the views expressed
More informationYour pharmacy, as near as your mailbox Aetna Rx Home Delivery
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Your pharmacy, as near as your mailbox Aetna Rx Home Delivery www.aetna.com 05.02.308.1-KC B (12/13) Start saving
More informationLATVIAN CONSTRUCTION COMPANIES DOING BUSINESS IN NORWAY
LATVIAN CONSTRUCTION COMPANIES DOING BUSINESS IN NORWAY RIGA, FEBRUARY 4, 2014 JENS LIENG & MARTIN WIKBORG Page 1 VISMA The leading provider of business software and services (BPO) in the Nordic More than
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationINTERNATIONAL PRICE COMPARISON: THE CYPRIOT EXAMPLE. Athos Tsinontides Health Insurance Organisation
INTERNATIONAL PRICE COMPARISON: THE CYPRIOT EXAMPLE Athos Tsinontides Health Insurance Organisation CYPRUS CYPRUS Kypros Demographics Population (2004): Gross Domestic Product (GDP): Total Health Expenditure
More informationthe sick funds payments are hospital focused and do not sufficiently upset out patient care or rehabilitation or psychiatric or homecare.
Bargain Medicine: Anatomy of a High Quality Healthcare System, Valiantly Operating with Inadequate Funding, or Socialism in Actions: How to over Promise and Under Deliver ; Mr. Kenneth Abramowitz, Managing
More informationRegulating the taxi industry: a literature survey with focus on Norway
Summary: Regulating the taxi industry: a literature survey with focus on Norway TØI report 646/2003 Author: Jon-Terje Bekken Oslo 2003, 41 pages Background and problem In recent years, the taxi industry
More informationOverview of pharmaceutical regulations in Europe OVERVIEW OF PHARMACEUTICAL PRICING AND REIMBURSEMENT REGULATION IN EUROPE 1
OVERVIEW OF PHARMACEUTICAL PRICING AND REIMBURSEMENT REGULATION IN EUROPE 1 1. Introduction Panos Kanavos LSE Health and Social Care The fundamental nature of national regulation on pharmaceutical products
More informationTerms of Access to Payment Systems
1 Terms of Access to Payment Systems The Different Positions of Small and Large Banks English summary of Swedish Competition Authority report 2006:1 2 Summary The Swedish banking market is dominated by
More informationHUMAN MEDICINES. Generic medicines. Our advice
HUMAN MEDICINES Generic medicines Our advice hpra.ie Our advice on Generic medicines This leaflet answers some of the most common questions about generic medicines. In particular, it includes information
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer EUROPEAN CITIZENS DIGITAL HEALTH LITERACY REPORT Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationfacts an d figu res Pharmacies and Pharmaceuticals in Norway 2007
2 007 facts an d figu res Pharmacies and Pharmaceuticals in Norway 2007 2 Facts and figures 2007 a b o u t th e nor w e g i a n pharma c y a s s o c i at i o n The Norwegian Pharmacy Association (Apotekforeningen)
More informationGeneric Medication Prices
Generic Medication Prices By David Belk MD We ve often heard that the cost of generic prescription medications have been rising dramatically in the US; far more than the average rate of inflation. But
More informationOIL AND THE NORWEGIAN ECONOMY GOVERNOR ØYSTEIN OLSEN NTNU, 29 SEPTEMBER 2015
OIL AND THE NORWEGIAN ECONOMY GOVERNOR ØYSTEIN OLSEN NTNU, 9 SEPTEMBER 15 GDP per capita relative to OECD Index. OECD = 1. Purchasing power adjusted 15 Norway Mainland Norway 15 1 1 5 197 1975 198 1985
More informationTherapeutic strategies for the treatment of pain
First EFIC Symposium - Societal Impact of Pain Brussells 4-5 May 2010 Therapeutic strategies for the treatment of pain Paolo D. Siviero Economic Strategy and Pharmaceutical Policy Department Office for
More informationCan pain be helpful as a quality indicator for health care systems?
Can pain be helpful as a quality indicator for health care systems? Brussels May. 4 th 2010 Dr. Alberto Grua Grunenthal Why is pain important? Pain is independent of social status, sex or ethnic origin
More informationTHE PETROL TAX DEBATE
THE PETROL TAX DEBATE Zoë Smith THE INSTITUTE FOR FISCAL STUDIES Briefing Note No. 8 Published by The Institute for Fiscal Studies 7 Ridgmount Street London WC1E 7AE Tel 2 7291 48 Fax 2 7323 478 mailbox@ifs.org.uk
More informationBENCHMARKING EMR ADOPTION FOR HELSIT 2013
Subtitle BENCHMARKING EMR ADOPTION FOR HELSIT 2013 Introduction to EMRAM & status as of Q2/2013 PRESENTED BY: DANIEL CZERMAK-WÄNN, NORDIC CLIENT RELATIONS MANAGER, HIMSS ANALYTICS EUROPE HIMSS Analytics
More informationFrench pharmaceutical system Focus on pricing and reimbursement
Couverture French pharmaceutical system Focus on pricing and reimbursement DDGOS date Sophie DELCROIX-LOPES CNAMTS Conflict of interest disclosure 2 The author declares that she has no competing interests.
More informationPotential Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region
More informationThe energy industry and energy price issues in Slovakia during recent years 1
The energy industry and energy price issues in Slovakia during recent years 1 Ing. Mikulá Cár, PhD. National Bank of Slovakia The energy industry and energy prices are becoming a subject of political decisions
More informationARRANGEMENTS FOR THE FUTURE SUPPLY AND REIMBURSEMENT OF GENERIC MEDICINES FOR NHS SCOTLAND. Consultation Document
ARRANGEMENTS FOR THE FUTURE SUPPLY AND REIMBURSEMENT OF GENERIC MEDICINES FOR NHS SCOTLAND Consultation Document Scottish Executive Health Department October 2003 Arrangements For The Future Supply And
More informationPharmacy Policy (General)
WORKSAFE VICTORIA Pharmacy Policy (General) WorkSafe can pay the reasonable costs of medications and other pharmacy items required as a result of a work-related injury or illness in accordance with Victorian
More informationDifferences in patterns of drug use between women and men
Differences in patterns of drug use between women and men Differences in patterns of drug use between women and men Key findings Introduction Cannabis Ecstasy Tranquillisers and sedatives Alcohol and drug
More informationPHARMACY BENEFIT DESIGN CONSIDERATIONS
PHARMACY BENEFIT DESIGN CONSIDERATIONS Is your pharmacy benefit designed for your employees or the big drug companies? The pharmacy (or prescription) benefit is one of the most sought after benefits by
More informationInternational comparisons of obesity prevalence
International comparisons of obesity prevalence June 2009 International Comparisons of Obesity Prevalence Executive Summary Obesity prevalence among adults and children has been increasing in most developed
More information4/17/2015. Health Insurance. The Framework. The importance of health care. the role of government, and reasons for the costs increase
Health Insurance PhD. Anto Bajo Faculty of Economics and Business, University of Zagreb The Framework The importance of healthcare, the role of government, and reasons for the costs increase Financing
More informationCosts of Card and Cash Payments in Denmark
109 Costs of Card and Cash Payments in Denmark Johan Gustav Kaas Jacobsen and Anders Mølgaard Pedersen, Payment Systems INTRODUCTION AND SUMMARY When consumers buy goods in shops, the payments and related
More informationHealth Care Job Information Sheet #10. Pharmacy
Health Care Job Information Sheet #10 Pharmacy A. Occupations A. Occupations 1) Pharmacist 2) Pharmacy Technician/ Assistant B. Labour Market Prospects C. ITPs in the Field D. Links 1) Pharmacist Regulated
More informationPharmaceutical Sector and
Introduction to the Pharmaceutical Sector and Rebate Contracts in Germany Dr. Frank Verheyen, Director WINEG Tim Steimle, Head of Pharmacy Department Hamburg, May 2010 General Facts about the pharmaceutical
More informationNICOTINE INHALING PRODUCTS AGE OF SALE RESTRICTIONS & PROXY PURCHASING GUIDANCE FOR PHARMACIES KEY POINTS
NICOTINE INHALING PRODUCTS AGE OF SALE RESTRICTIONS & PROXY PURCHASING GUIDANCE FOR PHARMACIES KEY POINTS The following guidance has been prepared by the Department of Health in conjunction with the Medicines
More informationRetail Pharmacy Trends. Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA
Retail Pharmacy Trends Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA About this presentation Knowing Your Market Helps You Plan Ahead Understanding the latest retail pharmacy trends
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationThe Logistics Barometer in two minutes
Nordic Logistics Barometer 13 The Logistics Barometer in two minutes Special role for Finnish logistics buyers Finnish logistics buyers differ markedly from their colleagues in Sweden, Denmark and Norway.
More informationBottled Water in France
Brochure More information from http://www.researchandmarkets.com/reports/53727/ Bottled Water in France Description: The Bottled Water in France industry profile is an essential resource for top-level
More informationBeer statistics. 2014 edition. The Brewers of Europe
Beer statistics 2014 edition The Brewers of Europe Beer statistics 2014 edition The Brewers of Europe Editor: Marlies Van de Walle 1st edition, October 2014 ISBN 978-2-9601382-3-8 EAN 9782960138238 1
More informationPharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring
Pharmaceutical Policy in : Role of Health Insurance in Pricing, Reimbursement and Monitoring Soonman KWON* and Sukyeong KIM** *Dean, School of Public Health Seoul National University ** Director, Research
More informationGroup insurance. Generic drugs. Their positive effect on your wallet
Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them
More informationIS ENERGY IN ESTONIA CHEAP OR EXPENSIVE?
IS ENERGY IN ESTONIA CHEAP OR EXPENSIVE? Rita Raudjärv, Ljudmilla Kuskova Energy is a resource without which it is hard to imagine life in today's world. People seem to take it for granted that energy
More informationYour pharmacy, as near as your mailbox Aetna Rx Home Delivery
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Your pharmacy, as near as your mailbox Aetna Rx Home Delivery www.aetna.com 05.02.308.1-KC B WEB (6/13) Our mail-order
More informationCan e-commerce in Healthcare Succeed? Developments in Mail Order and Internet Pharmacy in Europe
Can e-commerce in Healthcare Succeed? Developments in Mail Order and in Europe By James W Dudley June 2012 Summary Mail order and pharmacies have been a success in the USA and take around a quarter of
More informationVALUE ADDED TAX ANALYSIS AND SOME CURRENT ISSUES
VALUE ADDED TAX ANALYSIS AND SOME CURRENT ISSUES Michael Keen 7th IMF-Japan High-Level Tax Conference for Asian Countries Tokyo; April 5, 2016 Overview of VATs in the region VAT revenue is low in the region,
More informationINTERNATIONAL PRIVATE PHYSICAL THERAPY ASSOCIATION DATA SURVEY
INTERNATIONAL PRIVATE PHYSICAL THERAPY ASSOCIATION DATA SURVEY May 215 International Private Physical Therapy Association (IPPTA) IPPTA Focus Private Practitioner Business Education Benchmarking for Member
More information13 th Economic Trends Survey of the Architects Council of Europe
13 th Economic Trends Survey 13 th Economic Trends Survey of the Architects Council of Europe 13 th Economic Trends Survey Breakdown of responses COUNTRY ANSWERS France 1464 Belgium 399 Spain 365 Italy
More informationSWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness
SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment
More informationMeasurements and indicators for healthcare IT. Leif Panduro Jensen, MD, MHM Director of Centre, Rigshospitalet, Copenhagen, DK
Measurements and indicators for healthcare IT Leif Panduro Jensen, MD, MHM Director of Centre, Rigshospitalet, Copenhagen, DK Measurements and indicators for healthcare IT Working group from January to
More informationPills are getting so expensive what can you do about it?
Pills are getting so expensive what can you do about it? Our prescription drugs cost too much. There are a lot of people dipping into your wallet before you get the pill you need to get or stay healthy.
More informationRed blood cell transfusions in the Netherlands Towards (very) low use
Red blood cell transfusions in the Netherlands Towards (very) low use Marian G.J. van Kraaij, MD PhD hematologist/ transfusion medicine specialist Director Dept Transfusion Medicine Sanquin Blood Supply,
More informationAnalysis of Hospital Pharmaceuticals
Danish Ministry of Health and Prevention Analysis of Hospital Pharmaceuticals Country Report - Germany March 2009 COWI A/S Parallelvej 2 DK-2800 Kongens Lyngby Denmark Tel +45 45 97 22 11 Fax +45 45 97
More informationA new ranking of the world s most innovative countries: Notes on methodology. An Economist Intelligence Unit report Sponsored by Cisco
A new ranking of the world s An Economist Intelligence Unit report Sponsored by Cisco Economist Intelligence Unit Limited 2009 A new ranking of the world s Preface In April 2009, the Economist Intelligence
More informationA Comparison of the Tax Burden on Labor in the OECD By Kyle Pomerleau
FISCAL FACT Jun. 2014 No. 434 A Comparison of the Tax Burden on Labor in the OECD By Kyle Pomerleau Economist Key Findings Average wage earners in the United States face two major taxes: the individual
More informationConclusion of the Utility Regulator s Review of the firmus energy (Supply) Ltd Maximum Average Price in the Ten Towns area
Conclusion of the Utility Regulator s Review of the firmus energy (Supply) Ltd Maximum Average Price in the Ten Towns area 5 March 2015 About the Utility Regulator The Utility Regulator is the independent
More informationResults, 1st Quarter 2016. Patient Engagement. www.himss.eu/analytics. HIMSS Analytics ehealth TRENDBAROMETER Q1/2016
Results, 1st Quarter 2016 Patient Engagement www.himss.eu/analytics 1 TABLE OF CONTENT HIMSS Analytics Who we are page 3 Survey overview page 4 Results Overall page 9 Formal strategy page 10 Tools provided
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationSUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS
SUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS A Supplementary Protection Certificate (SPC) is an Intellectual Property right which can give up to five extra years of exclusivity after a
More informationThe economic importance of companion animals
The economic importance of companion animals FECAVA (The Federation of European Companion Animal Veterinary Associations) February 2007 Ellen Bjerkås DVM PhD Dipl ECVO Professor, Norwegian School of Veterinary
More informationCHEMIST WAREHOUSE SUBMISSION TO THE COMPETITION POLICY REVIEW
CHEMIST WAREHOUSE SUBMISSION TO THE COMPETITION POLICY REVIEW MAY 2014 Table of contents 1. Introduction... 3 2. Outlet location decision-making... 3 3. Discounting... 4 4. The true cost of regulation...
More informationWhat Is the Total Public Spending on Education?
What Is the Total Public Spending on Education? Indicator On average, OECD countries devote 12.9% of total public expenditure to, but values for individual countries range from less than 10% in the Czech
More informationTable of contents. Introduction 5. Facts and Figures 2010 - a brief outline 9. 1 The Netherlands. 2 Medicines 40. 3 Pharmacies 63
Table of contents Introduction 5 Facts and Figures 2010 - a brief outline 9 1 The Netherlands 1.1 Development of expenditure 15 1.2 Structural increase in expenditure on medicines 17 1.3 Use of medicines
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire Contents 1. Overview of the EFPIA Requirements... 3 2.
More informationTHE PERFORMANCE - OF THE UK INLAND MAILS BUSINESS OF CONSIGNIA
THE PERFORMANCE - OF THE UK INLAND MAILS BUSINESS OF CONSIGNIA Paper 1 of a series of papers prepared by Consignia in June 2002 for Postcomm s review of the price control for 2003 Summary The overall performance
More informationExpenditure on Health Care in the UK: A Review of the Issues
Expenditure on Health Care in the UK: A Review of the Issues Carol Propper Department of Economics and CMPO, University of Bristol NIERC 25 April 2001 1 Expenditure on health care in the UK: The facts
More informationInternational comparison of electricity and gas prices for commerce and industry
International comparison of electricity and gas prices for commerce and industry FINAL REPORT ON A STUDY PREPARED FOR CREG October 2011 Frontier Economics Ltd, London. October 2011 Frontier Economics
More informationAnnex 2C International comparisons of gas and electricity prices
Annex 2C International comparisons of gas and electricity prices Wholesale gas prices in the UK have risen between 23 and 24. This has caused industrial and domestic gas prices to increase and the gap
More informationBahrain Telecom Pricing
Bahrain Telecom Pricing International Benchmarking December 2015 2015 Disclaimer This benchmarking report contains information collected by an independent consultant commissioned by the Telecommunications
More informationHIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM. Western Australia Administrative Guidelines
HIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM Western Australia Administrative Guidelines Pharmaceutical Services Branch Health Protection Group Table of Contents BACKGROUND...1 Overview...1 AHMAC
More informationWhat Proportion of National Wealth Is Spent on Education?
Indicator What Proportion of National Wealth Is Spent on Education? In 2008, OECD countries spent 6.1% of their collective GDP on al institutions and this proportion exceeds 7.0% in Chile, Denmark, Iceland,
More informationRETAILERS ATTITUDES TOWARDS CROSS- BORDER TRADE AND CONSUMER PROTECTION
Eurobarometer RETAILERS ATTITUDES TOWARDS CROSS- BORDER TRADE AND CONSUMER PROTECTION REPORT Fieldwork: September - October 2012 Publication: June 2013 This survey has been requested by the European Commission,
More informationValue of production of agricultural products and foodstuffs, wines, aromatised wines and spirits protected by a geographical indication (GI)
Value of production of agricultural products and foodstuffs, wines, aromatised wines and spirits protected by a geographical indication (GI) TENDER N AGRI 2011 EVAL 04 Leaflet October 2012 The information
More informationVirginia. A guide for individuals and families. The health insurance benefits you want, at a cost you can afford
Virginia A guide for individuals and families CoventryOne is an individual product (for individuals and families) offered by Coventry Health Care, an Aetna company. The health insurance benefits you want,
More informationTHE NT EUROPE (ex-uk) EQUITY INDEX FUND
THE NT EUROPE (ex-uk) EQUITY INDEX FUND 1 2 02 Supplement to the Prospectus Northern Trust Investment Funds plc THE NT EUROPE (ex-uk) EQUITY INDEX FUND 3 This Supplement contains specific information in
More informationNovember 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.
CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,
More informationThe Norwegian-Swedish Electricity Certificate Market ANNUAL REPORT 2013
The Norwegian-Swedish Electricity Certificate Market ANNUAL REPORT 2013 2 Contents Preface 3 The Nordic electricity market 5 Key figures for 2013 6 How the electricity certificate market works 7 Goal fulfilment
More informationAnalysis of price components of essential medicines in India: policy options for improving access to medicines
Analysis of price components of essential medicines in India: policy options for improving access to medicines Anita Kotwani Department of Pharmacology, V.P.Chest Institute, University of Delhi, Delhi,
More informationHow To Calculate Tax Burden In European Union
The Tax Burden of Typical Workers in the EU 28 2015 James Rogers Cécile Philippe Institut Économique Molinari, Paris Bruxelles TABLE OF CONTENTS Abstract 2 Background 2 Main Results 3 On average, a respite
More informationIncentives and pharmaceutical reimbursement reforms in Spain
Health Policy 67 (2004) 149 165 Incentives and pharmaceutical reimbursement reforms in Spain Jaume Puig-Junoy Research Centre for Health and Economics (CRES), Department of Economics and Business, Pompeu
More informationSubmission to the National Health and Hospitals Reform Commission (nhhrc).
Submission to the National Health and Hospitals Reform Commission (nhhrc). A New Health Savings Based System for Australia. A new health savings based system is proposed based on the best aspects of the
More informationFACTS AND FIGURES. Apotekforeningen
2012 FACTS AND FIGURES Pharmacies and Pharmaceuticals in Norway 2012 Apotekforeningen INDEX Key figures 2012 4 Pharmacies in Norway 5 About the pharmacy trade 6 Numbers of pharmacies and development 6
More informationEuropean policy approaches to waste management and infrastructure
European policy approaches to waste management and infrastructure A5.0 Overview Appendix 5 Of greatest interest in terms of understanding the policies best suited for Irish waste management, infrastructure
More informationTHE REVENUE EFFECT OF CHANGING ALCOHOL DUTIES
THE REVENUE EFFECT OF CHANGING ALCOHOL DUTIES Zoë Smith THE INSTITUTE FOR FISCAL STUDIES Briefing Note No. 4 Published by The Institute for Fiscal Studies 7 Ridgmount Street London WC1E 7AE Tel 020 7291
More informationMedicine price regulation the South African experience
Medicine price regulation the South African experience Dr Anban Pillay Chief Director: Health Financing and Economics National Department of Health PillaA@health.gov.za pillayanban@yahoo.com.au Tel: +27
More informationrelating to household s disposable income. A Gini Coefficient of zero indicates
Gini Coefficient The Gini Coefficient is a measure of income inequality which is based on data relating to household s disposable income. A Gini Coefficient of zero indicates perfect income equality, whereas
More informationINNOBAROMETER 2015 - THE INNOVATION TRENDS AT EU ENTERPRISES
Eurobarometer INNOBAROMETER 2015 - THE INNOVATION TRENDS AT EU ENTERPRISES REPORT Fieldwork: February 2015 Publication: September 2015 This survey has been requested by the European Commission, Directorate-General
More informationOPERATIONAL CIRCULAR
Department of Health Government of Western Australia OPERATIONAL CIRCULAR Enquiries to: Rob Henry Tel: 9222 2037 Number: OP 1748/04 Supersedes: OP 1355/00 (09/11/2000) Date: 12 March 2004 Superseded by:
More informationElectricity, Gas and Water: The European Market Report 2014
Brochure More information from http://www.researchandmarkets.com/reports/2876228/ Electricity, Gas and Water: The European Market Report 2014 Description: The combined European annual demand for electricity,
More informationWorking Holiday Maker visa program report 30 June 2011
30/06/07 Working Holiday Maker visa program report 30 June 2011 Contents Page About this report 1 Enquiries 1 Definition of terms 2 Background to the Working Holiday Maker program 3 Recent developments
More informationCONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE
CONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE A CBO PAPER DECEMBER 2004 Medicaid s Reimbursements to Pharmacies for Prescription Drugs A CBO PAPER Medicaid s Reimbursements to Pharmacies for
More information